Background: There is a need for new oral agents active against extended-spectrum b-lactamase (ESBL) producers, as these increasingly cause community-onset infections. We therefore evaluated faropenem, a penem in Phase III development, against recently collected oxyimino-cephalosporinresistant bacteria. Conclusions: Faropenem has good activity against E. coli and Klebsiella spp. with ESBLs, including the CTX-M types now proliferating in Europe, but was less active against AmpC-derepressed and ESBL-producing Enterobacter spp. Its clinical utility will depend on levels achieved in the urinary tract, the site of most of the community infections caused by ESBL producers, and more work is needed in this area.
Introduction
Resistance to oxyimino-cephalosporins among Enterobacteriaceae is changing in nature and increasing in prevalence. 1 More importantly, CTX-M extended-spectrum b-lactamases (ESBLs) have become widespread in Europe since around year 2000. CTX-M-15 is predominant in most countries, but CTX-M-9 and M-14 are more common in Spain. 1 Whereas the longerestablished TEM and SHV ESBLs occur mostly in nosocomial isolates, often Klebsiella spp., CTX-M enzymes are often found in Escherichia coli from urinary infections in 'community' patients, typically those who are elderly, with underlying disease and recent hospitalization or antibiotics. 1 Community-onset infections with ESBL producers present therapeutic challenges, especially if the patient's condition would not ordinarily warrant hospitalization. Most CTX-M-positive E. coli isolates are multiresistant to trimethoprim, fluoroquinolones and amoxicillin/clavulanate, as well as to oral cephalosporins and penicillins. 1 Nitrofurantoin and fosfomycin generally remain active and can be given orally, but nitrofurantoin requires lengthy courses and is unpalatable, whereas fosfomycin is not universally available -neither drug is suitable for ascending infections. There is a consequent need for new oral options, both for community-onset infections and as follow-on treatment of infections initially managed with intravenous (iv) carbapenems. Oral penems and carbapenems potentially meet this need, and we 
Materials and methods
Cephalosporin-resistant Enterobacteriaceae isolates were collected in a 16 hospital survey, undertaken in South-East England in autumn 2004. 2 The mechanisms present in these isolates (see Results) were deduced by interpretive reading, cephalosporin/inhibitor synergy tests, group-specific PCR for CTX-M enzymes and plasmidmediated AmpC types 2 and reverse-line hybridization. 3 In addition, we tested E. coli transconjugants with various b-lactamases, including ESBLs; also isogenic mutant series of Enterobacter cloacae, Citrobacter freundii, Serratia spp. and Morganella morganii varying in expression of AmpC b-lactamases, and Proteus vulgaris mutants varying in expression of their chromosomal Class A b-lactamase. The derivation of these organisms was described previously. 4 MICs of faropenem (Replidyne, Louisville, CO, USA), imipenem (Merck, Hoddesdon, Herts, UK), cefpodoxime and cefixime (both from Sanofi-Aventis, Frankfurt Am Main, Germany) ceftazidime and amoxicillin/clavulanate (2:1) (GlaxoSmithKline, Stevenage, Herts, UK) were determined by the British Society for Antimicrobial Chemotherapy agar dilution method. 5 Results and discussion MIC distributions for the survey collection, by species and resistance mechanism, are shown in Table 1 . More than 77% (500/646) of the ESBL producers had CTX-M enzymes; over 97% (487/500) of these were Group 1 types, as shown by PCR, and over 90% of Group 1 types were CTX-M-15, as tested by the reverse line blot method. There was no evidence that the behaviour of faropenem varied in relation to ESBL type.
Modal MICs of faropenem for E. coli isolates with CTX-M ESBLs, non-CTX-M ESBLs and hyperproduced AmpC enzymes were all 1 mg/L, with only 5% of the ESBL producers requiring MICs . Cephalosporin-resistant Enterobacter and Citrobacter spp. were less susceptible to faropenem than E. coli and Klebsiella spp., with modal MICs of 2 -4 mg/L for both ESBL producers and AmpC-derepressed isolates. Around 5% of the AmpCderepressed Enterobacter spp. isolates required faropenem MICs of 16 mg/L, though with no higher values recorded. AmpC-derepressed Serratia spp. were less susceptible, with the modal MIC of faropenem straddling 8-16 mg/L. MIC modes and ranges for imipenem were two to three doubling dilutions below those of faropenem, with modal values of 0.12-0.25 mg/L for ESBL-producing E. coli and Klebsiella isolates and 0.25-0.5 mg/L for AmpC-hyperproducing and ESBL-producing Enterobacter, Citrobacter and Serratia spp. The differential in the activity between imipenem and faropenem was greater for AmpC-derepressed Serratia spp., with the modal MIC of imipenem 32 -64-fold lower than that of faropenem. The reduced activity of faropenem against ESBL-and AmpC-producing Enterobacter and Serratia spp. is not surprising, since previous studies have shown that these species are less susceptible to faropenem, regardless of their ability to produce b-lactamases. 6 MICs of co-amoxiclav were high for most members of all the groups of isolates tested, with modal values at or above the breakpoint of 16 mg/L; the amoxicillin/clavulanate resistance of many CTX-M-15-positive E. coli isolates is because they also have OXA-1, an inhibitor-resistant penicillinase, not because of the CTX-M-15 enzyme. 7 Faropenem was also tested against isogenic mutant series of Enterobacteriaceae, differing in expression of AmpC enzymes, and against E. coli transconjugants with various classical and ESBLs (Table 2) . MICs for AmpC-derepressed C. freundii, E. cloacae and Serratia marcescens mostly were one dilution above those for the corresponding AmpC-inducible parent organisms, whereas no Continued such differential was seen for imipenem. Faropenem retained equal activity against AmpC-inducible and -derepressed M. morganii and P. vulgaris, as did imipenem. AmpC-basal mutants were one to three dilutions more susceptible to faropenem than their AmpC-derepressed counterparts, as with imipenem, indicating that even inducible AmpC confers some slight protection. Among the various plasmid-mediated b-lactamases introduced into E. coli recipients, the only ones to cause a significant (i.e. greater than one doubling dilution) rise in the faropenem MIC were the carbapenemases, NMC-A (Class A) and IMP-1 (Class B), both of which engendered 64-fold MIC increases. Neither of these two enzymes caused such significant MIC rises for imipenem itself, supporting the view that imipenem resistance requires some further factor, usually impermeability arising via porin loss.
1 Neither CTX-M nor TEM/SHV-derived b-lactamases conferred any protection against faropenem or imipenem in transconjugants, though they did, predictably, protect against oxyimino-cephalosporins, including cefixime, cefpodoxime and ceftazidime.
The present data suggest that faropenem has potential to be useful against infections due to ESBL producers-which nowadays are mostly caused, in the UK at least, by E. coli and Klebsiella spp. with CTX-M-15 enzyme. 1 It might be used in community-onset infections due to these organisms and as follow-on treatment for nosocomial infections initially managed with an iv carbapenem. Whether this potential is borne out in practice will depend very much on the levels achieved in the urinary tract, which is the site of more than three-quarters of the community infections due to ESBL producers. 2 The MICs found here for ESBL producers and other cephalosporin-resistant organisms seem promising when set against published pharmacokinetics, 8 which indicate a serum peak of 10-14 mg/L and a t 1/2 of 0.9 h, based on a 300 mg oral dose, along with post-dose urine levels of 70 mg/L at 0-4 h and 12 mg/L at 4-8 h.
So far, there are few clinical data on faropenem's efficacy in urinary tract infections. Disappointingly, one Phase III trial found faropenem 300 mg twice daily less effective than co-trimoxazole in acute uncomplicated urinary tract infections; 9 however, a small Japanese trial found faropenem 300 mg three times daily was equivalent to levofloxacin-given (somewhat unusually) as a 100 mg three times daily regimen-in complicated urinary infections. 10 Perhaps the clearest conclusion is that faropenem has potential for treatment of urinary tract infections due to ESBL producers and other cephalosporin-resistant Enterobacteriaceae, but that further clinical work is needed to optimize regimens for this purpose. 
